MedPath

Biosante Pharmaceuticals

🇨🇦Canada
Ownership
Private
Employees
-
Market Cap
-
Website
http://wwww.biosantepharma.com

Clinical Trials

5

Active:0
Completed:5

Trial Phases

1 Phases

Phase 3:5

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 3
5 (100.0%)

Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

Phase 3
Completed
Conditions
Hypoactive Sexual Desire Disorder
Interventions
First Posted Date
2010-11-07
Last Posted Date
2013-01-10
Lead Sponsor
BioSante Pharmaceuticals
Target Recruit Count
626
Registration Number
NCT01235754
Locations
🇺🇸

BioSante Site #095, Hoover, Alabama, United States

🇺🇸

BioSante Site #014, Huntsville, Alabama, United States

🇺🇸

BioSante Site #146, Mobile, Alabama, United States

and more 99 locations

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

Phase 3
Completed
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Drug: placebo gel
First Posted Date
2008-04-14
Last Posted Date
2013-01-10
Lead Sponsor
BioSante Pharmaceuticals
Target Recruit Count
575
Registration Number
NCT00657501
Locations
🇺🇸

BioSante Site #146, Mobile, Alabama, United States

🇺🇸

BioSante Site #171, Chandler, Arizona, United States

🇺🇸

BioSante Site #145, Glendale, Arizona, United States

and more 66 locations

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

Phase 3
Completed
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Drug: placebo gel
First Posted Date
2008-02-12
Last Posted Date
2021-10-29
Lead Sponsor
BioSante Pharmaceuticals
Target Recruit Count
3656
Registration Number
NCT00612742
Locations
🇺🇸

BioSante Site #215, Birmingham, Alabama, United States

🇺🇸

BioSante Site 185, Birmingham, Alabama, United States

🇺🇸

BioSante Site 095, Hoover, Alabama, United States

and more 146 locations

Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

Phase 3
Completed
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Drug: placebo gel
First Posted Date
2008-02-12
Last Posted Date
2013-01-10
Lead Sponsor
BioSante Pharmaceuticals
Target Recruit Count
597
Registration Number
NCT00613002
Locations
🇺🇸

BioSante Site #215, Birmingham, Alabama, United States

🇺🇸

BioSante Site #095, Hoover, Alabama, United States

🇺🇸

BioSante Site #014, Huntsville, Alabama, United States

and more 60 locations

Efficacy and Safety of a Topical Estradiol Gel for Treatment of Postmenopausal Symptoms

Phase 3
Completed
Conditions
Hot Flashes
First Posted Date
2006-10-24
Last Posted Date
2006-10-24
Lead Sponsor
BioSante Pharmaceuticals
Target Recruit Count
431
Registration Number
NCT00391417

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.